Organisation paid for research Program year 2024 Source: CMS Open Payments

CHI Institute for Research

Neither a doctor nor a teaching hospital

Research payments

$92,110

10 payments

Through program year 2024, CHI Institute for Research is reported as receiving $92,110 in research payments, across 10 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $7,568 1
2023 Research $1,712 1
2022 Research $41,110 2
2021 Research $33 1
2020 Research $35,188 4
2019 Research $6,500 1

Breakdown

Who paid Research payments · program years 2019–2024
  1. Eli Lilly and Company $79,110 8 payments
  2. Penumbra, Inc. $6,500 1 payment
  3. Genentech, Inc. $6,500 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems (Triumph) $37,678 2 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $17,600 1 payment
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 2) $11,000 1 payment
  4. A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, A Cdk4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, Her2 Negative Metastatic Breast Cancer With Visceral Metastases $10,925 1 payment
  5. 1L Mtnbc Ipatasertib Tecentriq Paclitaxel $6,500 1 payment
  6. Cheetah $6,500 1 payment
  7. Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems (Triumph) $1,712 1 payment
  8. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $195 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record